These tools can process vast amounts of patient-specific genetic, molecular, and clinical data (e.g., MGMT methylation status) to suggest schemes that optimally suit each tumor’s individual characteristics, even in limited resource settings [107]. The gene discussed is MGMT; the disease is neoplasm.